Myomo Announces CFO Succession
February 06 2019 - 8:00AM
Business Wire
Myomo Inc. (NYSE American MYO) (“Myomo,” or the “Company”), a
wearable medical robotics company that offers expanded mobility for
those suffering from neurological disorders and upper limb
paralysis, today announced that Ralph A. Goldwasser, its Chief
Financial Officer, is retiring effective as of February 18, 2019.
Mr. Goldwasser, age 71, will provide transitional services to the
Company for an expected three-month term under a transition and
consulting agreement.
He will be succeeded by David Henry, effective February 18,
2019. Mr. Henry, age 57 has more than thirty years of experience in
high-technology manufacturing companies, including more than a
dozen years as Chief Financial Officer of publicly traded
companies. Mr. Henry is joining Myomo from Eos Energy Storage, a
privately held manufacturer of grid-scale energy storage systems
for utilities and renewable project developers, where he has served
as Chief Financial Officer since August 2017. Prior to Eos, Mr.
Henry served as Chief Financial Officer of American Superconductor
Corporation (NASDAQ: AMSC) from July 2007 to June 2017 and as Chief
Financial Officer of AMI Semiconductor (NASDAQ: AMIS), from April
2004 to July 2007. He has also held various financial executive
roles at Fairchild Semiconductor and National Semiconductor.
Paul R. Gudonis, Chairman and CEO of Myomo, said, “I would like
to thank Ralph, who has worked with me at Myomo for the past eight
years, first as a consulting CFO and later as our Chief Financial
Officer, enabling us to raise growth capital, including leading our
June 2017 IPO and listing on the NYSE American exchange and our
follow-on equity financing in December of 2017. We wish Ralph the
best in his retirement. We are pleased to have David Henry join
Myomo’s executive team as Chief Financial Officer. David has
extensive experience to support our efforts to grow the
Company.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. and a business development office in Europe. For
more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's future business expectations which are subject to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not
limited to, statements about the expansion of our business and
commercial operations, David Henry’s joining our company as Chief
Financial Officer and Mr. Goldwasser’s service to us in a
transitional role. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors. Our actual results could differ materially from
those anticipated in these forward looking statements for many
reasons, including, without limitation, risks related to regulatory
approval and market acceptance of our products, our ability to
secure and maintain reimbursement for our products, our ability to
obtain additional funding to sustain and grow our business, and the
other risk factors contained in our filings made with the
Securities and Exchange Commission. More information about factors
that potentially could affect Myomo's financial results is included
in Myomo's filings with the Securities and Exchange Commission. The
Company cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after
the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190206005090/en/
Contacts For Myomo:ir@myomo.com
Investor Relations:PCG AdvisoryVivian
Cervantes646-863-6274vivian@pcgadvisory.com
or
Public Relations:Matter CommunicationsMeredith
Krim617-874-5203myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024